Pillar Biosciences Stock
Pillar Biosciences specializes in sequencing technology platform and proprietary data analysis toolkit.
Sign up today and learn more about Pillar Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Pillar Biosciences Stock
Pillar Biosciences is prized with its patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which achieves high sensitivity and specificity with clinical samples. The platform provides a fast, simple and affordable targeted sequencing method for NGS-based oncology testing. The start-up has also released its beta version of Lung & Colon Cancer Somatic Mutation Panel and BRCA1 & BRCA2 Germline Mutation Panel to cancer centers and clinical testing companies in the US and China for validation studies. The company was founded in 2014 and is headquartered in Natick, Massachusetts.
Funding History
| August 2014 | $2.9M |
|---|---|
| May 2016 | $18.0M |
| November 2018 | $16.0M |
| February 2020 | $32.4M |
| May 2021 | $90.0M |
Management
Founder & CEO
Gang Song
Co-Founder and Chief Science Officer
Zhaohui Wang
Chief Operating Officer
Martin Zillmann
Chief Financial Officer
Vincent Ricci
Chief Executive Officer
Randy Pritchard
General Counsel
Christa Adkins
Interim CFO
Richard P. Shea
Chief Commercial Officer
Dan Harma
Press
prnewswire - Sep, 19 2023
Pillar Biosciences Launches oncoReveal™ Core LBx, an NGS Kit to Enable Localized Liquid Biopsy Testingthefly - Jul, 25 2023
Illumina, Pillar Biosciences announce partnershipgenomeweb - Apr, 15 2023
Pillar Biosciences Licenses KeyGene NGS IPgenomeweb - Nov, 1 2022
Beckman Coulter Life Sciences, Pillar Biosciences Partner to Develop NGS Solutionsbioworld - Jul, 21 2022
Pillar Biosciences seeks to add 8 indications to Oncoreveal Dxbusinesswire - Jun, 8 2022
Pillar Biosciences Strengthens Leadership Team with Appointment of Vincent Ricci as Chief Financial Officerbiospace - May, 31 2022
Pillar Biosciences Announces Online Publication of Data in the Journal of Clinical Oncologybiospace - Mar, 8 2022
Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counselbiospace - Jan, 6 2022
Pillar Biosciences Receives CLIA Certification for its Next-Generation Sequencing Clinical Laboratorybiospace - Sep, 1 2021
Pillar Biosciences Announces Appointment of Randy Pritchard as Chief Executive Officerow - Aug, 7 2021
FDA approves Pillar Biosciences’ cancer diagnostic testgenomeweb - May, 13 2020
Pillar Biosciences Closes $29.7M Series C Financing Roundprnewswire - May, 31 2019
Columbia University Medical Center Receives Conditional Approval by the New York State Department of Health for a Custom Pillar Biosciences NGS Panelprnewswire - Nov, 29 2017
Pillar Biosciences announces ISO 13485:2016 CertificationEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
